{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:37:41Z","timestamp":1759538261988,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"the Jiangsu Center for Safety Evaluation of Drugs"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.yrtph.2019.02.013","type":"journal-article","created":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T11:55:52Z","timestamp":1551095752000},"page":"8-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Toxicity studies for the use of prodrug of voriconazole in rats"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8588-1614","authenticated-orcid":false,"given":"Juemin","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingqing","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazhi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2019.02.013_bib1","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1086\/424662","article-title":"Adverse reactions to voriconazole","volume":"39","author":"Boyd","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.yrtph.2019.02.013_bib2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/FTD.0b013e31817b1a95","article-title":"Therapeutic drug monitoring of voriconazole","volume":"30","author":"Br\u00fcggemann","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.yrtph.2019.02.013_bib3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.phrs.2006.11.001","article-title":"Gender differences in drug response","volume":"55","author":"Franconi","year":"2007","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.yrtph.2019.02.013_bib4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0733-8635(03)00024-X","article-title":"New antifungal agents","volume":"21","author":"Gupta","year":"2003","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.yrtph.2019.02.013_bib5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/sj.bmt.1704603","article-title":"Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients","volume":"34","author":"Hamza","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.yrtph.2019.02.013_bib6","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1124\/dmd.109.031328","article-title":"Sex-dependent differences in cytochrome P450 3A activity as assessed by midazolam disposition in humans: a meta-analysis","volume":"38","author":"Hu","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.yrtph.2019.02.013_bib7","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/dmd.31.5.540","article-title":"Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole","volume":"31","author":"Hyland","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.yrtph.2019.02.013_bib8","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.clpt.2004.02.002","article-title":"Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status","volume":"75","author":"Ikeda","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"issue":"l","key":"10.1016\/j.yrtph.2019.02.013_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0168-8278(01)00050-2","article-title":"The antiestrogen toremifene protects against alcoholic liver injury in female rats","volume":"35","author":"Jarvelainen","year":"2001","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.yrtph.2019.02.013_bib10","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0149-2918(03)80126-1","article-title":"Voriconazole","volume":"25","author":"Jeu","year":"2003","journal-title":"Clin. Ther."},{"key":"10.1016\/j.yrtph.2019.02.013_bib11","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1086\/367933","article-title":"Voriconazole: a new triafungal agent","volume":"36","author":"Johnson","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.yrtph.2019.02.013_bib12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00007691-199806000-00001","article-title":"Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population","volume":"20","author":"Kimura","year":"1998","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.yrtph.2019.02.013_bib13","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1128\/AAC.00286-10","article-title":"International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole","volume":"54","author":"Lortholary","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.yrtph.2019.02.013_bib14","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1002\/jps.22109","article-title":"Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD)","volume":"99","author":"Luke","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.yrtph.2019.02.013_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijantimicag.2009.01.008","article-title":"Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes","volume":"34","author":"Matsumoto","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"4","key":"10.1016\/j.yrtph.2019.02.013_bib16","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3109\/13880209.2014.932391","article-title":"The antibacterial and antifungal activity of essential oils extracted from Guatemalan medicinal plants [J]","volume":"53","author":"Miller","year":"2015","journal-title":"Pharmaceut. Biol."},{"key":"10.1016\/j.yrtph.2019.02.013_bib17","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.bcp.2007.03.012","article-title":"Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes","volume":"73","author":"Murayama","year":"2007","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.yrtph.2019.02.013_bib18","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s10096-003-1014-3","article-title":"Voriconazole salvage treatment of invasive candidiasis","volume":"22","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"S1","key":"10.1016\/j.yrtph.2019.02.013_bib19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1365-2125.2003.01995.x","article-title":"Voriconazole potentiates wafarin-induced prothrombin time prolongation","volume":"56","author":"Purkns","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"year":"2001","series-title":"FDA Antiviral Drugs Advisory Committee Briefing Document for Voriconazole (Oral and Intravenous Formulations)","author":"Pfizer","key":"10.1016\/j.yrtph.2019.02.013_bib20"},{"key":"10.1016\/j.yrtph.2019.02.013_bib21","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/jps.2600840805","article-title":"Preliminary safety evaluation of parenterally administered sulfoalkyl ether b-cyclodextrin derivatives","volume":"84","author":"Rajewski","year":"1995","journal-title":"J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.yrtph.2019.02.013_bib22","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1345\/aph.19237","article-title":"Voriconazole: a new triazole antifungal","volume":"34","author":"Sabo","year":"2000","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.yrtph.2019.02.013_bib23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0091270005283837","article-title":"Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities","volume":"46","author":"Tan","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.yrtph.2019.02.013_bib24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.yrtph.2019.02.013_bib25","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.yrtph.2019.02.013_bib26","first-page":"193","article-title":"Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole","volume":"14","author":"Watt","year":"2013","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.yrtph.2019.02.013_bib27","series-title":"Hepatotoxicity: the Adverse Effects of Drugs and Other Chemicalson the Liver","first-page":"61","article-title":"Expressions of hepatotoxicity","volume":"vol. 2","author":"Zimmerman","year":"1999"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230019300583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230019300583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:26:37Z","timestamp":1759494397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230019300583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":27,"alternative-id":["S0273230019300583"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2019.02.013","relation":{},"ISSN":["0273-2300"],"issn-type":[{"type":"print","value":"0273-2300"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity studies for the use of prodrug of voriconazole in rats","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2019.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}